Role for protein kinase C delta in the functional activity of human UGT1A6: Implications for drugdrug interactions between PKC inhibitors and UGT1A6

Xenobiotica

Volumn 40, Issue 5, 2010, Pages 306-318

  Volak, L P ^a   Court, M H ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug drug interaction; Glucuronidation; Protein kinase C (PKC); UDP glucuronosyltransferase (UGT); UGT1A6

Indexed keywords

CALPHOSTIN C; CURCUMIN; GLUCURONOSYLTRANSFERASE 1A6; HYPERICIN; PARACETAMOL; PROTEIN KINASE C DELTA; PROTEIN KINASE C INHIBITOR; ROTTLERIN; SEROTONIN; VALPROIC ACID; ENZYME ACTIVATOR; GLUCURONOSYLTRANSFERASE; ISOENZYME; PROTEIN KINASE INHIBITOR; UDP-GLUCURONOSYLTRANSFERASE, UGT1A6;

ARTICLE; CELL DIFFERENTIATION; CELL LYSATE; COLON; CONTROLLED STUDY; DRUG GLUCURONIDATION; DRUG INHIBITION; EMBRYO; EMBRYO CELL; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; INSECT CELL; KIDNEY CELL; PROTEIN EXPRESSION; SCREENING; WHOLE CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CULTURE TECHNIQUE; DRUG EFFECTS; DRUG INTERACTION; ENZYMOLOGY; GLYCOSYLATION; IC50; INSECT; LIVER MICROSOME; METABOLISM; MOUSE; RAT;

HEXAPODA;

ACETAMINOPHEN; ANIMALS; CELL CULTURE TECHNIQUES; CELL LINE; DRUG INTERACTIONS; ENZYME ACTIVATORS; GLUCURONOSYLTRANSFERASE; GLYCOSYLATION; HUMANS; INHIBITORY CONCENTRATION 50; INSECTS; ISOENZYMES; MICE; MICROSOMES, LIVER; PROTEIN KINASE C-DELTA; PROTEIN KINASE INHIBITORS; RATS; SEROTONIN;

EID: 77950797793     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498251003596817     Document Type: Article

References (42)

1. Abraham C, Scaglione-Sewell B, Skarosi SF, Qin W, Bissonnette M, Brasitus TA. (1998). Protein kinase C alpha modulates growth and differentiation in Caco-2 cells. Gastroenterology 114:503-509
2. Assert R, Kotter R, Bisping G, Scheppach W, Stahlnecker E, Muller KM, Dusel G, Schatz H, Pfeiffer A. (1999). Anti-proliferative activity of protein kinase C in apical compartments of human colonic crypts: evidence for a less activated protein kinase C in small adenomas. Int J Cancer 80:47-53.
3. Basu NK, Kole L, Basu M, Chakraborty K, Mitra PS, Owens IS. (2008). The major chemical-detoxifying system of UDPglucuronosyltransferases requires regulated phosphorylation supported by protein kinase C. J Biol Chem 283:23048-23061
4. Basu NK, Kole L, Owens IS. (2003). Evidence for phosphorylation requirement for human bilirubin UDP-glucuronosyltransferase (UGT1A1) activity. Biochem Biophys Res Commun 303:98-104.
5. Basu NK, Kovarova M, Garza A, Kubota S, Saha T, Mitra PS, Banerjee R, Rivera J, Owens IS. (2005). Phosphorylation of a UDP-glucuronosyltransferase regulates substrate specificity. Proc Natl Acad Sci USA 102:6285-6290
6. Basu NK, Kubota S, Meselhy MR, Ciotti M, Chowdhury B, Hartori M, Owens IS. (2004). Gastrointestinally distributed UDPglucuronosyltransferase 1A10, which metabolizes estrogens and nonsteroidal anti-inflammatory drugs, depends upon phosphorylation. J Biol Chem 279:28320-28329
7. Bates E, Bode C, Costa M, Gibson CM, Granger C, Green C, Grimes K, Harrington R, Huber K, Kleiman N, Mochly-Rosen D, Roe M, Sadowski Z, Solomon S, Widimsky P. (2008). Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Circulation 117:886-896
8. Birchall AM, Bishop J, Bradshaw D, Cline A, Coffey J, Elliott LH, Gibson VM, Greenham A, Hallam TJ, Harris W, Hutchings A, Lamont AG, Lawton G, Lewis EJ, Maw A, Nixon JS, Pole D, Wadsworth J, Wilkinson SE. (1994). Ro 32-0432, a selective and orally active inhibitor of protein kinase C prevents T-cell activation. J Pharmacol Exp Ther 268:922-929
9. Bock KW, Kohle C. (2005). UDP-glucuronosyltransferase 1A6: structural, functional, and regulatory aspects. Methods Enzymol 400:57-75.
10. Brooks B, Delaney-Robinson C, Molyneaux L, Yue DK. (2008). Endothelial and neural regulation of skin microvascular blood flow in patients with diabetic peripheral neuropathy: effect of treatment with the isoform-specific protein kinase C beta inhibitor, ruboxistaurin. J Diabet Complicat 22:88-95.
11. Buchdunger E, Mett H, Trinks U, Regenass U, Muller M, Meyer T, Beilstein P, Wirz B, Schneider P, Traxler P, Lydon NB. (1995). 4,5-Bis(4-fluoroanilino) phthalimide: A selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity. Clin Cancer Res 1:813-821
12. Cockerill SL, Tobin AB, Torrecilla I, Willars GB, Standen NB, Mitcheson JS. (2007). Modulation of hERG potassium currents in HEK-293 cells by protein kinase C. Evidence for direct phosphorylation of pore forming subunits. J Physiol 581:479-493
13. Court MH. (2001). Acetaminophen UDP-glucuronosyltransferase in ferrets: species and gender differences, and sequence analysis of ferret UGT1A6. J Vet Pharmacol Ther 24:415-422
14. Court MH, Duan SX, von Moltke LL, Greenblatt DJ, Patten CJ, Miners JO, Mackenzie PI. (2001). Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDPglucuronosyltransferase isoforms. J Pharmacol Exp Ther 299:998-1006.
15. Davidson LA, Jiang YH, Derr JN, Aukema HM, Lupton JR, Chapkin RS. (1994). Protein kinase C isoforms in human and rat colonic mucosa. Arch Biochem Biophys 312:547-553
16. Doi S, Goldstein D, Hug H, Weinstein IB. (1994). Expression of multiple isoforms of protein kinase C in normal human colon mucosa and colon tumors and decreased levels of protein kinase C beta and eta mRNAs in the tumors. Mol Carcinog 11:197-203.
17. Erdbrugger W, Keffel J, Knocks M, Otto T, Philipp T, Michel MC. (1997). Protein kinase C isoenzymes in rat and human cardiovascular tissues. Br J Pharmacol 120:177-186
18. Geiges D, Meyer T, Marte B, Vanek M, Weissgerber G, Stabel S, Pfeilschifter J, Fabbro D, Huwiler A. (1997). Activation of protein kinase C subtypes alpha, gamma, delta, epsilon, zeta, and eta by tumor-promoting and nontumor-promoting agents. Biochem Pharmacol 53:865-875
19. Gschwendt M, Muller HJ, Kielbassa K, Zang R, Kittstein W, Rincke G, Marks F. (1994). Rottlerin, a novel protein kinase inhibitor. Biochem Biophys Res Commun 199:93-98
20. Gutmann H, Poller B, Buter KB, Pfrunder A, Schaffner W, Drewe J. (2006). Hypericum perforatum: which constituents may induce intestinal MDR1 and CYP3A4 mRNA expression? Planta Med 72:685-690
21. Hesse LM, He P, Krishnaswamy S, Hao Q, Hogan K, von Moltke LL, Greenblatt DJ, Court MH. (2004). Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 14:225-238
22. Jirousek MR, Gillig JR, Gonzalez CM, Heath WF, McDonald JH, III, Neel DA, Rito CJ, Singh U, Stramm LE, Melikian-Badalian A, Baevsky M, Ballas LM, Hall SE, Winneroski LL, Faul MM. (1996). (S)-13-[(dimethylamino)methyl]-10,11,14,15- tetrahydro-4-,9:16,21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13] oxadiazacyclohexadecene-1,3(2H)-dione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta. J Med Chem 39:2664-2671
23. Koren R, Langzam L, Paz A, Livne PM, Gal R, Sampson SR. (2000). Protein kinase C (PKC) isoenzymes immunohistochemistry in lymph node revealing solution-fixed, paraffin-embedded bladder tumors. Appl Immunohistochem Mol Morphol 8:166-171
24. Krishnaswamy S, Duan SX, von Moltke LL, Greenblatt DJ, Court MH. (2003a). Validation of serotonin (5-hydroxtryptamine) as an in vitro substrate probe for human UDP-glucuronosyltransferase (UGT) 1A6. Drug Metab Dispos 31:133-139
25. Krishnaswamy S, Duan SX, von Moltke LL, Greenblatt DJ, Sudmeier JL, Bachovchin WW, Court MH. (2003b). Serotonin (5-hydroxytryptamine) glucuronidation in vitro: assay development, human liver microsome activities and species differences. Xenobiotica 33:169-180
26. Krishnaswamy S, Hao Q, Al-Rohaimi A, Hesse LM, von Moltke LL, Greenblatt DJ, Court MH. (2005). UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J Pharmacol Exp Ther 313:1340-1346
27. Kuranami M, Powell CT, Hug H, Zeng Z, Cohen AM, Guillem JG. (1995). Differential expression of protein kinase C isoforms in human colorectal cancers. J Surg Res 58:233-239
28. Kurita M, Nishino S, Ohtomo K, Rai M, Shirakawa H, Mashiko H, Niwa S, Nakahata N. (2007). Sodium valproate at therapeutic concentrations changes Ca2+ response accompanied with its weak inhibition of protein kinase C in human astrocytoma cells. Prog Neuropsychopharmacol Biol Psychiatry 31:600-604
29. Kuriyama M, Taniguchi T, Shirai Y, Sasaki A, Yoshimura A, Saito N. (2004). Activation and translocation of PKCdelta is necessary for VEGF-induced ERK activation through KDR in HEK293T cells. Biochem Biophys Res Commun 325:843-851
30. Mackay HJ, Twelves CJ. (2007). Targeting the protein kinase C family: are we there yet? Nat Rev Cancer 7:554-562
31. Masur K, Lang K, Niggemann B, Zanker KS, Entschladen F. (2001). High PKC alpha and low E-cadherin expression contribute to high migratory activity of colon carcinoma cells. Mol Biol Cell 12:1973-1982
32. Nishimura M, Naito S. (2006). Tissue-specific mRNA expression profiles of human phase I metabolizing enzymes except for cytochrome P450 and phase II metabolizing enzymes. Drug Metab Pharmacokinet 21:357-374
33. Ozpolat B, Akar U, Mehta K, Lopez-Berestein G. (2007). PKC delta and tissue transglutaminase are novel inhibitors of autophagy in pancreatic cancer cells. Autophagy 3:480-483
34. Pongracz J, Clark P, Neoptolemos JP, Lord JM. (1995). Expression of protein kinase C isoenzymes in colorectal cancer tissue and their differential activation by different bile acids. Int J Cancer 61:35-39
35. Rickard KL, Gibson PR, Wilson NJ, Mariadason JM, Phillips WA. (2000). Short-chain fatty acids reduce expression of specific protein kinase C isoforms in human colonic epithelial cells. J Cell Physiol 182:222-231
36. Soh JW, Weinstein IB. (2003). Roles of specific isoforms of protein kinase C in the transcriptional control of cyclin D1 and related genes. J Biol Chem 278:34709-34716
37. Soltoff SP. (2007). Rottlerin: an inappropriate and ineffective inhibitor of PKCdelta. Trends Pharmacol Sci 28:453-458
38. Takai Y, Kishimoto A, Iwasa Y, Kawahara Y, Mori T, Nishizuka Y. (1979). Calcium-dependent activation of a multifunctional protein kinase by membrane phospholipids. J Biol Chem 254:3692-3695
39. Tillman DM, Izeradjene K, Szucs KS, Douglas L, Houghton JA. (2003). Rottlerin sensitizes colon carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis via uncoupling of the mitochondria independent of protein kinase C. Cancer Res 63:5118-5125
40. Volak LP, Ghirmai S, Cashman JR, Court MH. (2008). Curcuminoids inhibit multiple human cytochromes P450 (CYP), UDPglucuronosyltransferase (UGT), and sulfotransferase (SULT) enzymes, while piperine is a relatively selective CYP3A4 inhibitor. Drug Metab Dispos 36:1594-1605
41. von Moltke LL, Greenblatt DJ, Harmatz JS, Shader RI. (1993). Alprazolam metabolism in vitro: Studies of human, monkey, mouse, and rat liver microsomes. Pharmacology 47:268-276
42. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, Ball SE. (2004). Drug-drug interactions for UDP- glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32:1201-1208